Shanghai, China and South San Francisco, California, USA, Aug 10, 2020 -- JW Therapeutics, a clinical-stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today announced entering into a development and commercialization agreement with Lyell Immunopharma to advance adoptive T cell therapy for the treatment of hepatocellular carcinoma in China and ASEAN countries.
The collaboration combines Lyell’s proprietary T cell anti-exhaustion technology, which is intended to preserve or maintain T cell function, with JW Therapeutics’ recent acquisition of Syracuse and its ARTEMIS technology platform. The companies’ complementary capabilities in developing and manufacturing cell-based products may help advance new treatment options for patients in China and other parts of Asia.
JW Therapeutics and Lyell Immunopharma intend to seek additional opportunities for collaboration in research, development, and commercialization of products in China.
Terms of the collaboration were not disclosed.
About JW Therapeutics
JW Therapeutics was founded in February 2016 in Shanghai. As a clinical-stage biopharmaceutical company focusing on the development, transformation and commercialization of leading cell immunotherapy, JW Therapeutics aims to become the innovation leader in the industry. The company is committed to collaborating with both local and international peers to build a world-class leading innovation platform for cell immunotherapy, to create the industry standard and ecosystem together, and to benefit Chinese patients and those around the world.
The company has put into place a mature and stable process development system as well as the advanced cGMP manufacturing quality management system. It has obtained the first approval for the clinical trials of CAR-T product targeting CD19 with the largest number of patient enrolments under IND pathway, which enhances its leading position in clinical studies of CAR-T in China.
About Lyell Immunopharma
Lyell Immunopharma, Inc. is a cell therapy company dedicated to understanding and developing technologies to overcome fundamental barriers to curative cancer cell therapies. Lyell brings together an unrivaled scientific team with a collection of novel technologies focused on advancing the science of T cell differentiation, functionality, and target specificity in order to develop curative treatments for solid tumors. These technologies can be used as a platform for multiple new cell therapies that can be applied across a broad range of cancers.
For more information on Lyell Immunopharma please visit www.lyell.com.